Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Open-label, Two Single Dose, Fixed-sequence Study Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine Following a Single Oral Dose of Lu AF67708 ([Ethyl-1-14C]-Idalopirdine) and Lu AF67709 ([Benzyl-7-14C]-Idalopirdine) in Healthy Men

NCT02415907 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT02415907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02415907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Open-label, Two Single Dose, Fixed-sequence Study Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine Following a Single Oral Dose of Lu AF67708 ([Ethyl-1-14C]-Idalopirdine) and Lu AF67709 ([Benzyl-7-14C]-Idalopirdine) in Healthy Men
Lead sponsor
H. Lundbeck A/S
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2015
Completion date
June 30, 2015
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy